An Immunotherapy Combination as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Host: Tracey Evans, MD <br> Guest: Raja Mudad, MD <br> <p>For thirty years, there were limited therapeutic advancements leading to FDA approvals in extensive-stage small cell lung cancer (ES-SCLC). However, this all changed with the IMpower133 trial, which led to the emergence of immunotherapy as a first line treatment option in ES-SCLC. Joining Dr. Tracey Evans is medical oncologist Dr. Raja Mudad to discuss the IMpower133 trial and the reasons to consider TECENTRIQ^®(atezolizumab), the first immunotherapy combination for patients with ES-SCLC.</p> <p>This program is intended for US Physicians.</p> <p style="text-align: right;"> M-US-00010808(v1.0)</p>